Lassen Therapeutics reels in $85M Series B for PhII testing in thyroid eye disease
Summary
Lassen Ther\xada\xadpeu\xadtics closed an over\xadsub\xadscribed $85 mil\xadlion Se\xadries B on Tues\xadday morn\xading as the San Diego biotech brings its treat\xadment can\xaddi\xaddate for thy\xadroid eye dis\xadease in\xadto Phase II test\xading.The Fra\xadzier Life Sci\xadences-found\xaded start\xadup is at\xadtempt\xading to go in\xadto a field with mul\xadti\xadple oth\xader biotechs in clin\xadi\xadcal de\xadvel\xadop\xadment, but Lassen hopes to carve out its own lane by ap\xadproach\xading the au\xadtoim\xadmune dis\xadease with a fi\xadbro-in\xadflam\xadma\xadto\xadry an\xadgle. Al\xadso known as TED, the dis\xadease caus\xades in\xadflam\xadma\xadtion and some\xadtimes bulging in the eyes.Unlock this article instantly by becoming a free subscriber. Youll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.